

## An Updated Review on Hyperlipidemia

Radheshyam<sup>1\*</sup>, Navneet Kumar Verma<sup>2</sup><sup>1</sup>Department of Pharmacology, Shakti College of Pharmacy, Balrampur, U. P, India<sup>2</sup>Department of Pharmaceutics, Buddha Institute of Pharmacy, GIDA, Gorakhpur, U. P, India**\*Corresponding Author**

Radheshyam

**Article History**

Received: 17.09.2021

Accepted: 25.10.2021

Published: 11.11.2021

**Abstract:** Hyperlipidemia is a disease portrayed by an extension, in any incident, one of the plasma lipids, including triglycerides, cholesterol, cholesterol esters just as plasma lipoproteins including outstandingly low thickness and low thickness lipoproteins close by diminished high thickness lipoproteins levels. This stature of plasma lipids is among the leading risk factors related to cardiovascular illnesses. The present review focuses on the sorts of hyperlipidemia, lipid processing, the pathophysiology of hyperlipidemia, treatment frameworks for raised lipid profiles. In the interim statins and fibrates remain the major antihyperlipidemic administrators for the treatment. The fortune spot of the plant domain has different plants to treat this ailment. The indigenous course of action of the drug gives bountiful data about plants available for the treatment of hyperlipidemia. The review also lightens the role of nutraceuticals in hyperlipidemia therapy. The search was performed in PubMed, PsycInfo, Web of Science, Scopus, and Medline databases. A quality assessment yielded a total of 60 papers to be considered for the review by using strict inclusion and exclusion criteria.

**Keywords:** Lipoproteins, hyperlipidemia, hypercholesterolemia, atherosclerosis, and statin.

## INTRODUCTION

### CHOLESTEROL

Cholesterol was a waxy fat-like substance that was found in all cells of the body and in some of the foods. Cholesterol was a necessary nutrient for many functions including:

- Repairing the cell membranes.
- Construction of vitamin D on the skin's surface
- Producing hormones such as that estrogen, testosterone
- Probably helping cell links in a brain that is essential for learning and memory.

Regardless of these benefits when cholesterol levels rise the blood and that can have dangerous consequences depending on the type of cholesterol and its production stimulated by saturated fat [1].

### LIPOPROTEIN

Lipids are insoluble in the blood (plasma), they must be transported to the cells by special carriers called lipoproteins. Lipoproteins are spherical particles of high molecular weight. Each lipoprotein particle contains a non-polar core and a hydrophilic surface. The hydrophilic surface makes the lipoprotein soluble in plasma and acts as an interface between the plasma and lipid core. The center comprises of hydrophobic lipids, triglycerides, and cholesterol esters, encompassed by a hydrophilic surface layer of phospholipids, unesterified cholesterol, and explicit proteins named apolipoproteins or apoproteins. The apolipoproteins provide structural integrity to the lipoproteins and determine the lipoprotein's metabolic fate by serving as binding sites for receptors and activating enzymes involved in lipid metabolism [2].

### LIPID METABOLISM

Almost all the dietary fats are ingested from the intestinal lumen into the intestinal lymph, what's more, swollen into chylomicrons. These lipoproteins shift into the circulation system where they got hydrolyzed by endothelial

**Copyright © 2021 The Author(s):** This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

lipoprotein lipase which hydrolyzes the triglyceride into glycerol and nonesterified unsaturated fats. After which the chylomicron remainders are invested in the liver and bundled with cholesterol, cholesteryl esters, and ApoB100 to shape VLDL. After the arrival of VLDL into the circulation system, it will be changed over into IDL by the activity of lipoprotein lipase and hepatic lipase, where phospholipids and apolipoproteins moved back to HDL. Besides, after the hydrolysis by hepatic lipase, IDL will be altered over to LDL and disaster more apolipoproteins [2]. Cholesterol is come back to the liver by the turn around the cholesterol transport pathway utilizing HDLs which are initially orchestrated by the liver, what's more, discharged into the blood. In the blood, HDL cholesterol is esterified by LCAT to cholesteryl ester, besides, moved to VLDL and chylomicrons to return to the liver through the LDL receptor. Cholesteryl ester is moved to LDL particles by CETP and afterward exposed to LDL-receptors interceded endocytosis. At long last, cholesteryl esters are hydrolyzed to cholesterol and separated from the body as bile acid [3].

### **CLASSIFICATION OF LIPOPROTEIN**

The cholesterol along with some other types of fats cannot be dissolved in the blood. Moreover so as to be shipped to and from cells, they must be particularly conveyed by specific particles called lipoproteins, which comprise an external layer of protein with an internal center of cholesterol and triglycerides [4, 5]. In expansion, the lipoproteins have been discovered fundamental for cholesterol to move around the body. The lipids can be classified as TC, triglycerides, LDL, HDL, and very low density lipoprotein (VLDL) cholesterol.

#### **Total Cholesterol**

As per rules of the National Cholesterol Education Program (NCEP), TC fixation underneath 200 mg/dL has been considered as attractive, while, focuses more prominent than 240 mg/dL are near as hyperlipidemia. In any case, epidemiological proof recommends that the danger of heart occasions diminishes as TC levels fall roughly to 150 mg/dL. Also, TC ought to be under 180 mg/dL for kids [6, 7].

#### **Triglyceride**

Triglycerides are another kind of fat that is conveyed in the blood by VLDL. The abundance of calories, liquor, or sugar in the body gets changed over into triglycerides and put away in fat cells all through the body [8]. The triglyceride focus under 150 mg/dL is viewed as ordinary, though, centralizations of 200-499 mg/dL are considered as high. Besides, centralizations of 500 mg/dL or higher are viewed as hazardous for the turn of events and movement of different CVDs [9].

#### **LDL cholesterol**

LDL is normally known as the terrible cholesterol, which is created by the liver and conveys cholesterol and different lipids from the liver to various territories of the body like muscles, tissues, organs, and heart. The significant levels of LDL demonstrate considerably more cholesterol in the circulatory system than would normally be appropriate and consequently, increment the danger of heart disease [8, 10]. As indicated by NCEP rules, LDL cholesterol fixations underneath 100mg/dL are viewed as ideal, while focuses on the scope of 160-189 mg/dL are considered to the higher side. In any case, expanding proof backings that typical human LDL cholesterol fixation can be as low as 50 to 70 mg/dL [11]. Besides, it has been exhaustively observed that the danger of CVDs diminishes as LDL cholesterol fixation diminishes.

#### **HDL cholesterol**

HDL is ordinarily alluded to as the great cholesterol, which is delivered by the liver to convey cholesterol and different lipids from tissues back to the liver for degradation [10]. Significant levels of HDL cholesterol have been considered as a decent marker of a sound heart. The centralizations of 60 mg/dL or higher have been considered as ideal, though, HDL concentrations underneath 40 mg/dL are considered as a significant hazard factor for CVDs. Notwithstanding, HDL is regularly deciphered with regards to TC and LDL focuses, and subsequently might be viewed as less critical when LDL is low [8, 10].

#### **VLDL Cholesterol**

VLDL is like LDL cholesterol as it contains for the most part fat and very little protein. VLDL cholesterol is the lipoproteins that convey cholesterol from the liver to organs and tissues in the body [11]. They are shaped by a blend of cholesterol and triglycerides. Additionally, VLDLs are heavier than LDL and are likewise connected with atherosclerosis and heart disease [12].

### **ENZYMES INVOLVED IN LIPOPROTEIN TRANSPORT & METABOLISM**

There are several enzymes and transfer proteins that play an important role in lipoprotein metabolism. Some of the enzymes and their functions are mentioned in Table 1.

**Table 1: Importance Of Enzymes In Lipid Transport & Metabolism [14, 15]**

Enzymes	Functions
Lipoprotein lipase	Hydrolysis of TG rich particles some phospholipase activity activated by APO C-II
Hepatic lipase	Hydrolysis of Tri-, Di- and mono acylglycerols, Acyl-CoA thioester and phospholipids conversion of HDL2 to HDL1 activated by APO A-III
Pancreatic lipase	Hydrolysis of FAs at positions 1 and 3 of emulsified TGs in the intestine.
Lecithin cholesterol Acyltransferase LCAT	Catalysis of lecithin with cholesterol to give lysolecithin and cholesteryl ester activated by APO A-I and APO c -I.
Pancreatic cholesterol esterase	Esterification of cholesterol in the intestinal lumen
Acyl co A-cholesterol acyl transferase ACAT	Esterification of cholesterol within the cells
Cholesterol ester transfer protein CETP	Transfers esterified cholesterol from HDLs to VLDLs and LDLs.
HMG Co-A reductase	Rate limiting enzyme of cholesterol synthesis

## HYPERLIPIDEMIA

Hyperlipidemia is a condition when abnormally high levels of lipids i.e. The fatty substance are found in the blood. This situation is also known as hypercholesterolemia [16]. The human body is complex machinery and for maintaining the homeostasis of various organ and organ systems. Any undesirable change will disturb the balance resulting in a diseased state. Lipids are fats in the circulatory system, usually separated into cholesterol and triglycerides. Cholesterol flows in the circulatory system and is engaged with the structure and capacity of cells. Triglycerides (TG) are best seen as a vitality that is either utilized promptly or put away in fat cells [17] tg is fabricated in the liver from the nourishments or by being consumed from the digestive system. Virchow in 19th century who identified cholesterol crystals in the atherosclerotic lesion and stated that endothelial cell injury initiates atherogenesis in a modification of this hypothesis, it was proposed that the endothelium normally influences the behavior of arterial smooth muscle cells by providing a barrier to the passage of plasma proteins and that the major effect of hemodynamic or other factors that injure endothelium is to reduce the effectiveness of the barrier [18]. Arteries are normally smooth and unobstructed on the inside, but in case of increased lipid level, a sticky substance called plaque is formed inside the walls of arteries. This leads to reduced blood flow, leading to stiffening and narrowing of the arteries. It has been proved that elevated plasma levels of cholesterol and LDL are responsible for atherosclerosis in man, and epidemiological data suggest that elevated plasma levels of HDL have a protective effect [19, 20].

## CLASSIFICATION

### TYPES OF HYPERLIPIDEMIA

Hyperlipidemia can be broadly divided into:

1. Primary hyperlipidemia is due to Single gene defect: It is familial and called monogenic or genetic. Polygenic gene defect, Multiple genetic defects, dietary, and physical activity are caused due to it.

**Table 2: Disorder**

TYPE	DISORDER	CAUSE	OCCURRENCE	ELEVATED PLASMA LIPOPROTEIN
<b>I.</b>	Familial lipoprotein lipase deficiency	Genetic	Very rare	Chylomicrons
<b>II<sub>a</sub></b>	Familial hypercholesterolemia	Genetic	Less common	LDL
<b>II<sub>b</sub></b>	Polygenic hypercholesterolemia	Multifactorial	Commonest	LDL
<b>III</b>	Familial Dysbetalipoproteinemia	Genetic	Rare	IDL, Chylomicrons Remnants
<b>IV</b>	Hypertriglyceridemia	Multifactorial Genetic	Common	VLDL
<b>V</b>	Familial combined hyperlipidemia	Genetic	Less common	VLDL, LDL

LDL- Low-density Lipoprotein, VLDL- Very Low-Density Lipoprotein, IDL- Intermediate Density Lipoprotein [21].

## 2. SECONDARY HYPERLIPIDEMIA

It is associated with diabetes, myxoedema, nephritic syndrome, chronic alcoholism, with the use of drugs like corticosteroids, oral contraceptives, Beta-blocker [22].

## **Type 1 Hypercholesterolemia**

### **REASONS**

#### **Hypothyroidism**

- Anorexia nervosa
- Acute intermittent porphyria
- Obstructive liver disease
- Nephrotic syndrome
- Drugs: Progestins, thiazide, diuretics, glucocorticoids, beta-blockers, isotretinoin, protease inhibitors, cyclosporine, mirtazapine, sirolimus.

#### **Hypertriglyceridemia**

- Obesity
- Pregnancy
- Lipodystrophy
- Acute hepatitis
- Diabetes mellitus
- Ileal bypass surgery
- Glycogen storage disease
- Systemic lupus erythematosus
- Monoclonal gammopathy: multiple myeloma
- Drugs: Alcohol, estrogens, isotretinoin, beta-blockers, glucocorticoids, bile-acid resins, thiazides, asparaginase, azole antifungals, mirtazapine, anabolic steroids, sirolimus, bexarotene.

#### **Hypocholesterolemia**

- Malnutrition
- Malabsorption
- Chronic liver disease
- Myeloproliferative diseases Chronic infectious diseases: AIDS, tuberculosis

#### **Low HDL**

- Malnutrition
- Obesity
- Drugs: anabolic steroids, probucol, isotretinoin, progestins.

### **CAUSES OF HYPERLIPIDEMIA [23]**

1. Way of life propensities or treatable ailments. Way of life patrons incorporate stoutness, not working out, and smoking
2. Cushing's Syndrome
3. Kidney illness
4. Pregnancy
5. An underactive thyroid organ
6. Ecological and hereditary elements
7. Liquor consumption
8. Monoclonal Gammopathy
9. Nephrotic Syndrome
10. Obstructive Jaundice
11. Decrease in thyroidism
12. Diabetes (type 2).
13. Anorexia Nervosa
14. Drugs • Thiazide Diuretics • Ciclosporin • Glucocorticoids • Beta Blockers • Retinoic Acid
15. High dietary straight forward sugars
16. Estrogen treatment

### **PATHOPHYSIOLOGY OF HYPERLIPIDEMIA**

LDL cholesterol ordinarily courses in the body for 2.5 days, and in this manner ties to the LDL receptor on the liver cells, experiences endocytosis, and is processed. LDL is excluded, and the arrangement of cholesterol by the liver is smothered in the HMG-CoA reductase pathway [24]. FH, LDL receptor work is diminished or missing, and LDL flow for a normal length of 4.5 days, bringing about essentially expanded degree of LDL cholesterol in the blood with ordinary degrees of different lipoproteins [25]. In changes of ApoB, the decreased power of LDL elements to the receptor

causes the stretched degree of LDL cholesterol. It isn't known how the change causes LDL receptor dysfunction in changes of PCSK9 and ARH is a pathologic procedure described by the aggregation of lipids, cholesterol, and calcium and t]. In spite of the fact that atherosclerosis happens in a specific way in all individuals, FH patients may create quickened atherosclerosis because of the overabundance level of LDL. The level of atherosclerosis roughly depends on the number of LDL receptors despite everything communicated and the usefulness of these receptors. In various heterozygous types of FH, the receptor effort is just somewhat injured, and LDL levels will stay quite low. In the more genuine homozygous structures, the receptor isn't communicated at all [26]. A few investigations of FH associates recommend that extra chance variables are for the most part having an effect on everything when an FH persistent create atherosclerosis [27]. Notwithstanding the exemplary hazard factors, for example, smoking, high blood weight, and diabetes, hereditary examinations have appeared that a typical variation from the norm in the prothrombin quality (G20210A) builds the danger of cardiovascular occasions in patients with FH [28]. A few examinations create that a considerable level of lipoprotein(a) was an extra risk cause for ischemic coronary illness [29]. The dangerous situation was moreover seen as higher in patients with a particular genotype of the angiotensin-changing over chemical (ACE) [30, 31].

## **COMPLICATIONS**

### **Inconveniences of hyperlipidemia**

#### **Atherosclerosis**

Hyperlipidemia is the most significant hazard factor for atherosclerosis, which is a significant reason for cardiovascular sickness. Atherosclerosis the advancement of sinewy plaques inside the dividers of enormous and medium arteries [32].

#### **Coronary Artery Disease (CAD)**

Atherosclerosis, the significant reason for coronary corridor illness, portrayed by the collection of lipid and the arrangement of sinewy plaques inside the mass of the conduits bringing about narrowing of the veins that gracefully blood to the myocardium, and results in restricting bloodstream and deficient measures of oxygen to address the issues of the heart. Raised lipid profile has been associated with the advancement of coronary atherosclerosis [33].

#### **Myocardial Infarction (MI)**

MI is a condition that happens when blood and oxygen supplies are in part or totally hindered from streaming in at least one cardiovascular courses, bringing about harm or passing of heart cells. The impediment might be because of burst atherosclerotic plaque. The investigations show that around one-fourth of overcomers of myocardial dead tissue was hyperlipidemic [33].

#### **Ischemic stroke**

Stroke is the fourth driving reason for death. Typically, strokes happen because of blockage of a course by blood coagulation or a bit of atherosclerotic plaque that loosens up in a little vessel inside the mind. Numerous clinical preliminaries uncovered that bringing down of low-thickness lipoprotein and all-out cholesterol by 15% altogether diminished the danger of the main stroke [34].

## **CLINICAL MANIFESTATION**

The National Cholesterol Education Program suggests that a fasting lipoprotein profile (FLP) including absolute cholesterol, LDL, HDL, and triglycerides ought to be estimated in all grown-ups 20 years old or more established at any rate once like clockwork [35].

Estimation of plasma cholesterol (which is about 3% lower than serum judgments), triglyceride, and HDL levels following a 12-hour or longer quick is significant, in light of the fact that triglycerides might be raised in nonfasted people; total cholesterol is just humbly influenced by fasting [35].

Two conclusions, 1 to about two months separated, with the patient on a steady eating regimen and weight, and without intense sickness, are prescribed to limit changeability and to acquire a solid benchmark. In the event that the all-out cholesterol is more prominent than 200 mg/dL, a subsequent assurance is suggested, and if the qualities are in excess of 30 mg/dL separated, the normal of three qualities ought to be utilized (Barbara *et al.*, 2005). After a lipid irregularity is affirmed, significant parts of the assessment are the history (counting age, sex, and, if female, menstrual and estrogen substitution status), physical assessment, and research center examinations.

A total history and physical assessment ought to survey (1) nearness or nonattendance of cardiovascular hazard factors or unequivocal cardiovascular sickness in the individual; (2) family ancestry of untimely cardiovascular malady or lipid issue; (3) nearness or nonappearance of auxiliary reasons for hyperlipidemia, including simultaneous meds; and (4) nearness or nonappearance of xanthomas, stomach agony, or history of pancreatitis, renal or liver ailment, fringe

vascular infection, stomach aortic aneurysm, or cerebral vascular ailment (carotid bruits, stroke, or transient ischemic assault).

Diabetes mellitus is currently viewed as a CHD chance proportional. That is, the nearness of diabetes in patients without known CHD is related to a similar degree of hazard as patients without diabetes yet having affirmed CHD [35].

In the event that the physical assessment and history are lacking to analyze a familial issue, at that point agarose-gel lipoprotein electrophoresis is helpful to figure out which class of lipoproteins is influenced. On the off chance that the triglyceride levels are underneath 400 mg/dL and neither sort III hyperlipidemia nor chylomicrons are identified by electrophoresis, at that point, one can compute VLDL and LDL fixations:  $VLDL = \text{triglyceride}/5$ ;  $LDL = \text{absolute}$  [35].

Cholesterol - (VLDL + HDL). Beginning testing utilizes absolute cholesterol for case finding, yet ensuing administration choices ought to be founded on LDL.

Since all out cholesterol is made out of cholesterol got from LDL, VLDL, and HDL, assurance of HDL is valuable when all-out plasma cholesterol is raised. HDL might be raised by moderate liquor ingestion (less than two beverages for each day), physical exercise, smoking suspension, weight reduction, oral contraceptives, phenytoin, and terbutaline. HDL might be brought down by smoking, stoutness, an inactive way of life, and medications, for example,  $\beta$  blockers [36].

Conclusion of lipoprotein lipase inadequacy depends on low or missing protein movement with typical human plasma or apolipoprotein C-II, a cofactor of the catalyst.

To have an okay of coronary illness, the lipid levels must be kept up as follows;

1. LDL under 130 mg/dL or < 70 on the off chance that you have set up the conclusion of diabetes
2. HDL more prominent than 40 mg/dL (men) or 50 mg/dL (ladies)
3. Complete cholesterol under 200 mg/dL and
4. Triglycerides under 200 mg/dL or 150 on the off chance that you have set up coronary illness or diabetes.

**Table 3: Diagnosis**

S. NO	TEST NAME	NORMAL VALUES	INDICATORS
1	Total Cholesterol	Total Cholesterol: < 200 mg/dL (desirable) (< 180 optimal)	200-239 mg/dL = Borderline High (borderline risk for coronary heart disease [CHD]) > 240 mg/dL = Hypercholesterolemia
2	Total Cholesterol for children	< 180 mg/Dl	> 180 mg/dL may lead to premature Atherosclerosis
3	Triglyceride Levels	Less than 150 mg/dL	150-199 mg/dL is Borderline High 200-499 mg/dL is High 500 mg/dL or above is very High
4	HDL Cholesterol	$\geq 60$ mg/dL is desirable	In general, HDL levels < 40 mg/dL increases risk for CHD. Women with levels < 47 mg/Dl and men < 37 mg/dL have increased risk.
5	LDL Cholesterol	< 100 mg/dL (optimal) 100-129 mg/dL (near optimal/above optimal)	130-159 mg/dL Borderline High 160-189 mg/dL High $\geq 190$ mg/dL Very High
6	C-reactive Protein (CRP)	CRP < 1 mg/dl	CRP > 1 mg/dl (> 10 mg/dl often seen) suggests inflammation
7	VLDL Cholesterol	The VLDL normal range is between 0–40 mg/dL and the recommended optimum range is between 0–30 mg/Dl	> 40 suggests can increase the risk of developing heart disease

## PHARMACOLOGICAL TREATMENT

Many hypolipidemic synthetic drugs are available in the market for the treatment of hyperlipidemia and other associated disease [37]. The existing hypolipidemic drugs with there mechanism of action use and side effects are listed in Table 4.

**Table 4: Drugs Treatment**

Categories	Drugs	MOA	Use	Side effect
HMG-CoA reductase inhibitors	Lovastatin Atorvastatin Rosuvastatin	HMG-CoA reductase catalyzes the synthesis of mevalonic acid from HMG-CoA and is the rate-limiting step in cholesterol biosynthesis Leads to the up-regulation of LDL receptors in the liver.	Great for all hyperlipidemia involving increased levels of LDL or cholesterol Atherosclerosis; stroke prevention Primary prevention of CADV	Headache Nausea sleep disturbance elevations in hepatocellular enzymes and alkaline phosphatase. CI in hepatic dysfunction
Bile acid sequestrants	Cholestyramine Colestipol Colesevelam	Anion-exchange resin – binds bile acids in intestinal lumen preventing enterohepatic circulation (this increases excretion of bile which is made from cholesterol), this causes an up-regulation of hepatic LDL receptors and increased production of cholesterol.	Uses hyperlipidemias involving isolated increases of LDL.	Constipation Flatulence Dyspepsia Hypertriglyceridemia Hyperchloremic acidosis
Fibrates	Gemfibrozil, Fenofibrate, Micronized	activation of nuclear transcription receptor to increase LPL synthesis (removes TGs from lipoproteins); enhanced removal of VLDL from plasma	DOC fro type III lipoproteinemia (familial dysbetalipoproteinemia) •Hypertriglyceridemias • useful for Pruritus in biliary obstruction	Skin rash, gastrointestinal (nausea, bloating, cramping) myalgia; lowers blood cyclosporine levels; potentially nephrotoxic in cyclosporine treated patients. Avoid in patients with CrCl <30 mL/min. (Fenofibrate)
Nicotinic acid (Niacin)	Niacin	It is a potent inhibitor of lipolysis in adipose tissues which decreases mobilization of FFAs (a major precursor of TGs) to the liver which in turn decreases VLDL (after few hours) Increases HDL levels.	Uses hyperlipidemias with very high VLDL and LDL. • Patients with very low HDL.	dry skin myositis Prostaglandin-mediated cutaneous flushing, warm sensation Headache Pruritus, Nausea, Vomiting, diarrhea hyperpigmentation Decreased glucose tolerance Hepatotoxicity (check AST, ALT levels) Rhabdomyolysis Hyperuricemia
cholesterol absorption inhibitors	Ezetimibe	• Localizes at the brush border, selectively inhibits intestinal absorption of cholesterol and related sterols (only blocks exogenous sterol intake)	Used in hypercholesterolemia a together with statins & diet regulation.	Diarrhea Abdominal pain CI liver dysfunction
PCSK9 inhibitor	Alirocumab Evolocumab	Proprotein exchange subtilisin Kexin 9 (PCSK9) is a serine protease formed predominantly in the liver that goes ahead to the degradation of hepatocyte LDL receptors and improved LDL-C levels	• This group of lipid-lowering therapy appears hopeful in a variety of clinical situations.	the effect is injection site reaction

## NON PHARMACOLOGICAL TREATMENT

The targets of dietary treatment are to diminish the admission of complete fat, soaked unsaturated fats (i.e., immersed fat), and cholesterol logically and to accomplish an alluring body weight. This includes;

1. Concentrated immersed fat admission to 7 percent of everyday calories.
2. Lessen complete fat admission to 25 to 35 percent of everyday calories.
3. Constrained dietary cholesterol to fewer than 200 mg for each day.
4. Eating 20 to 30 g daily of dissolvable fiber, which is found in oats, peas, beans, and certain natural products; and
5. Expanded admission of plant stanols or sterols, substances found in nuts, vegetable oils, corn, and rice, to 2 to 3 g day by day. Different nourishments that can help control cholesterol incorporate cold-water fish, for example, mackerel, sardines, and salmon. These fish contain omega-3 unsaturated fats that may bring down triglycerides. Soybeans found in tofu and soy nuts and numerous meat substitutes contain an incredible cell reinforcement that can bring down LDL [38].

## HERBS USED AS ANTIHYPERLIPIDEMIC ACTIVITY

Herbal medicines have been the chief source of primary health care worldwide. Since ancient times, plants have been cooking as a rich source of effective and safe medicines. Most of the world's population still relies on traditional medicines. A list of some medicinal plants which have antihyperlipidemic activity is mention in table [39-51].

**Table 5: Herbs Used As Antihyperlipidemic Activity**

S. NO	PLANTS NAME	BIOLOGICAL SOURCE	PARTS USED	ROLE IN HYPERLIPIDEMIA
	Basil	<i>Ocimum basilicum</i> Lamiaceae	Leaf	Lowering LDL and total cholesterol, an increase of HDL
	Blueberry	<i>Vaccinium corymbosum</i> Ericaceae	Fruits	Lowering triglyceride and LDL levels
	Celery	<i>Apium celery</i> Family Apiaceae	Seed	Decreasing serum triglyceride, total cholesterol, LDL-C, and hepatic triglyceride
	Dandelion	<i>Taraxacum officinale</i> Compositae	Root leaves.	Decreasing serum triglyceride, total cholesterol, LDL-C and increasing HDL-C
	Dill	<i>Anethum graveolens</i> Apiaceae.	Dried ripe fruit.	Decreasing serum triglyceride
	Evening primrose oil	<i>Oenothera biennis</i> Onagraceae	Root, herb.	Decreasing serum triglyceride, total cholesterol
	Fenugreek	<i>Rigonella foenum</i> family Fabaceae	Seeds and leaves	Decreasing serum triglyceride, total cholesterol, HDL-C
	Ginger	<i>Zingiber officinale</i> Zingiberaceae.	Rhizomes	Decreasing serum LDL-C and increasing HDL-C
	Ginseng	<i>Ginseng panax</i> Araliaceae	Dried root	Decreasing serum triglyceride, total cholesterol, LDL-C and increasing HDL-C
	Grape	<i>Vities vinifera</i> Vitaceae	Fruits	Lowering oxidized LDL and elevate HDL-C level
	Green tea	<i>Camellia sinensis</i> Myrtaceae	Leaves	Lowers the adiposity and affects the appearance of lipid metabolism genes
	Nigella	<i>Nigella Sativa</i> Ranunculaceae	Seed	The decrease in triglyceride and increase in HDL-C
	Psyllium	<i>Plantago Psyllium</i> Plantaginaceae	Ripe seeds	Decrease in LDL
	Aswagandha	<i>Withania Somnifera</i> Solanaceae	Root	help improve heart health by reducing cholesterol and triglyceride levels
	Indigo Berry	<i>Randia dumetorum</i> Rubiaceae	Fruit	a decrease in total cholesterol level in serum at 18 hours and 24 hour
	Guggul	<i>Commiphora wigatii</i> Burseraceae	Gum resin	a decrease in total cholesterol level in serum at 18 hours and 24 hour
	Berberis	<i>Berberis aristata</i> Berberacie	Root	low-density lipoprotein level decreased
	Black pipper	<i>Piperum nigrum</i> Piperaceae	Fruit	It begins the digestion route by helping quick break down of better fat molecules into easily digestible simple molecules and prevents the growth of fat in the body.
	snake jasmine	<i>Rhinacanthus nasutus</i> Acanthaceae	Whole plant	lipoprotein level decreased
	Liquorice	<i>Glycyrrhiza Glabra</i> Fabaceae	Root	decrease in lipid profile in serum when compared to the dyslipidaemic HFD control



## **ROLE OF NUTRACEUTICALS IN HYPOLIPIDEMIC THERAPY**

Nutraceuticals is a region of pharmacology concerning food segments or dynamic fixings that might be utilized as helpful specialists. This incorporates countless mixes, for example, a functioning fixing, food supplements (i.e., supplements the ordinary eating routine), and useful nourishments (i.e., food sources advanced with parts with explicit helpful or defensive capacities), just as arrangements dependent on restorative herbs. Most mixes are vegetable begun, however, there are additional substances with creature source (e.g., fish oil). Ongoing examinations have demonstrated promising outcomes for these medications in different neurotic confusions, for example, diabetes, atherosclerosis, cardiovascular infections, malignancy, and neurological issue. There is an assortment of nutraceuticals with a potential lipid-bringing down impact, and in this manner helps in cardiovascular ailment anticipation and treatment [52].

### **Policosanols**

These are a blend of regular long-chain aliphatic alcohols that got from a wide assortment of plants. It has been recommended that policosanols may hinder the movement of HMG-CoA reductase, however, this isn't completely affirmed various clinical examinations proposed a lipid-bringing down impact of policosanols in various kinds of decrease in LDL-cholesterol like that of statins (about 25%) and a 10% expansion of HDL-C [53].

### **Polyphenols**

This is an exceptionally enormous group of substances accessible in the plant world. The fundamental element is the nearness of different phenolic bunches having a strong enemy of oxidant impact It has additionally been hypothesized that polyphenols can restrain HMG-CoA reductase, just as ACAT2 and MTP, supporting a hypocholesterolemic effect [54].

### **Probiotics**

Probiotics could bring down cholesterol ingestion through direct cell impacts or intervene by bile metabolism [55]. A few examinations on various patients have archived huge decreases in all-out cholesterol, up to 40% [56, 57]. despite, accurate components of activity were not distinguished, More as of late, it has been proposed a job of the outflow of the quality of bile salt hydrolase movement in the lactobacilli strains to clarify the cholesterol-bringing down activity, regardless of whether this theory itself doesn't appear to be totally convincing [58].

### **Guggul**

This is a tar extricated from the bark of Commiphora Mukul, a little prickly tree, otherwise called the tree of myrrh he dynamic segments, guggulsterone E and Z, have been exhibited to have an adversarial activity of FXR, an atomic receptor engaged with the bile digestion.

### **Plant Sterols**

Plant sterols decay intestinal maintenance of cholesterol through The lessening of the substance of cholesterol inside the micelles and a subsequent lower degree of absorbable cholesterol [59]. Besides, a couple of examinations suggest that phytosterols can fight with cholesterol in the transporter of the intracellular incorporation (NPC1L1), and moreover increase the activity of transmembrane proteins at risk for the release of cholesterol (ABCA1) and plant sterols (ABCG5 and ABCG8) in the stomach related framework and liver with the net effect of extending the appearance of the two sterols into the intestinal lumen by enterocytes and in the bile conductors in the liver [60, 61]. The lower intestinal ingestion of cholesterol-incited by plant sterols reduces cholesterol pool of liver, which response by growing the affirmation of LDL receptors, finally realizing higher take-up of plasma LDL and as such in a net hypocholesterolemic sway.

### **Fermented Red Rice**

The maturing of red rice by a parasite (*Monascus purpureus*). Produces a substance called monacolin K, which thwarts the amalgamation of cholesterol [62]. The monacolin K is in any case called lovastatin, astatine open in the market far and wide. The red yeast rice in like manner conveys diverse monacolins that may update the restriction of HMG CoA reductase. Moreover, late data show that stood out from the old-style lovastatin, monacolin K removed from red yeast rice have even a higher bioavailability with a higher sufficiency at the comparable dosage [63].

### **Berberine**

This substance, with an intolerant taste and excellent yellow concealing, is nearby in the bark, roots, and stems, including the underground (rhizome) of plants of the family Berberis, for instance, barberry (*Berberis vulgaris* L.). Of late, most thought has been on the metabolic properties of berberine. In 2004, Konge, have demonstrated that berberine diminished plasma cholesterol by 29%, triglycerides by 35%, and LDL cholesterol by 25%, however, it didn't alter HDL-cholesterol levels [64]. Berberine extends the number of LDL receptors on the hepatic cell surface, correspondingly to

statins. During statin treatment, the presentation of LDL-receptors on cell layers follows the reducing of the endogenous cholesterol association and the subsequent abatement of intracellular cholesterol pool, however, the action of berberine has all the earmarks of being associated with the ability to spoil a protein (PCSK9) at risk for the poor adulteration of LDL receptors in the liver. In the future, berberine may have synergistic contacts with statins [65, 66].

## CONCLUSION

Hyperlipidemia has been influencing humankind for a very long time. In spite of the fact that numerous medications are accessible to treat Hyperlipidemia, the issue of upgraded cholesterol levels in the blood is as yet common and is being a reason for some coronary issues. As of late, certain synthetic compounds (drugs) of the common beginning have seen light in rewarding these cholesterol levels, lessening the danger of coronary failures. To diminish the hazard because of hyperlipidemia, the different ways are to follow a solid way of life and medications that can decrease the cholesterol and triglyceride levels in the blood.

## REFERENCES

1. Singh, R., & Nain, S. (2018). A mini-review on hyperlipidemia: Common clinical problem. *Interventional Cardiology Journal*, 4(3), 10.
2. McLaren, J. E., Michael, D. R., Ashlin, T. G., & Ramji, D. P. (2011). Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. *Progress in lipid research*, 50(4), 331-347.
3. Hegele, R. A. (2009). Plasma lipoproteins: genetic influences and clinical implications. *Nature Reviews Genetics*, 10(2), 109-121.
4. Dargel, R. (1989). Lipoproteins and the etiopathogenesis of atherosclerosis. *Zentralblatt fur allgemeine Pathologie u. pathologische Anatomie*, 135(6), 501-504.
5. Kritchevsky, D. (1988). Cholesterol vehicle in experimental atherosclerosis. A brief review with special reference to peanut oil. *Archives of pathology & laboratory Medicine*, 112(10), 1041-1044.
6. Ahmed, S. M., Clasen, M. D., & Donnelly, M. D. (1998). Management of dyslipidemia in adults. *Amer, Family Physician*, 57, 1-16.
7. Smelt, A. H. M. (2010). Triglycerides and gallstone formation. *Clinica chimica acta*, 411(21-22), 1625-1631.
8. Fryar, C. D., Hirsch, R., Eberhardt, M. S., Yoon, S. S., & Wright, J. D. (2010). Hypertension, high serum total cholesterol, and diabetes: racial and ethnic prevalence differences in U.S. adults. 1999-2006. NCHS Data Brief, 36, 1-8.
9. Costet, P. (2010). Molecular pathways and agents for lowering LDL-cholesterol in addition to statins. *Pharmacology & therapeutics*, 126(3), 263-278.
10. Ridker, P. M., Genest, J., Boekholdt, S. M., Libby, P., Gotto, A. M., Nordestgaard, B. G., ... & JUPITER Trial Study Group. (2010). HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. *The Lancet*, 376(9738), 333-339.
11. Ginsberg, H. N., & Goldberg, I. J. (2001). Disorders of lipoprotein metabolism. In: Harrison's Principles of Internal Medicine. 15th Ed. New York: mcgraw Hill. 2245-2256.
12. Sundaram, M., & Yao, Z. (2010). Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. *Nutrition & metabolism*, 7(1), 1-17.
13. Robbins and Cotran. (2004). Pathological Basics of disease. Published by Elsevier. 158.
14. Wang, H., & Eckel, R. H. (2009). Lipoprotein lipase: from gene to obesity. *American Journal of Physiology-Endocrinology and Metabolism*, 297(2), E271-E288.
15. Ching, K. C. (1999). Fatty acids in food and their health complications. USA: Marcel Dekker publishers, 2, 459.
16. Gupta, A., Sehgal, V., & Mehan, S. (2011). Hyperlipidemia: an updated review. *Inter. J. Biopharm. Toxicol. Res*, 1, 81-89.
17. Virchow, R. P., & Thrombose, I. G. (1856). In *Gesammelte Abhandlungen zur Wissenschaftlichen Medicin*. Frankfurt-am-Main, Meidinger Sohn & Company, 458-464.
18. Rohilla, A. N. K. U. R., Dagar, N., Rohilla, S., Dahiya, A. M. A. R. J. E. E. T., & Kushnoor, A. (2012). Hyperlipidemia-a deadly pathological condition. *International journal of current pharmaceutical research*, 4(2), 15-18.
19. Ross, R., & Glomset, J. A. (1976). The pathogenesis of atherosclerosis. *N Engl J Med*, 295, 97.
20. Grundy, S. M., & Vega, G. L. (1988). Hypertriglyceridemia: causes and relation to coronary heart disease - Semin. *Thromb Hemost*, 14, 249-264.
21. Tripathi, K. D. (2008). Essentials of Medical pharmacology. *JP brothers medical publishers*, 6, 13-14.
22. Joseph, T. D. (2005). Pharmacotherapy: A pathophysiological approach. The Mc Graw Hill companies, Inc, 6, 429.
23. Keane, W. F., St Peter, J. V., & Kasiske, B. L. (1992). Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?. *Kidney International Supplement*, (38), 134-41.
24. Ford, E. S., Giles, W. H., & Dietz, W. H. (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *Jama*, 287(3), 356-359.
25. Expert Panel on Detection. (2002). Evaluation and Treatment of High Blood Cholesterol in Adult. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*, 106, 3143-21.

26. Veerkamp, M. J., de Graaf, J., Bredie, S. J., Hendriks, J. C., Demacker, P. N., & Stalenhoef, A. F. (2002). Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. *Arteriosclerosis, thrombosis, and vascular biology*, 22(2), 274-282.
27. Suviolahti, E., Lilja, H. E., & Pajukanta, P. (2006). Unraveling the complex genetics of familial combined hyperlipidemia. *Annals of medicine*, 38(5), 337-351.
28. Garcia-Otin, A. L., Civeira, F., Peinado-Onsurbe, J., Gonzalvo, C., Llobera, M., & Pocovi, M. (1999). Acquired lipoprotein lipase deficiency associated with chronic urticaria. A new etiology for type I hyperlipoproteinemia. *European journal of endocrinology*, 141(5), 502-505.
29. Nauck, M. S., Nissen, H., Hoffmann, M. M., Herwig, J., Pullinger, C. R., Aversa, M., ... & Marz, W. (1998). Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. *Clinical chemistry*, 44(7), 1388-1396.
30. Heath, R. B., Karpe, F., Milne, R. W., Burdge, G. C., Wootton, S. A., & Frayn, K. N. (2003). Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period. *Journal of lipid research*, 44(11), 2065-2072.
31. Schneeman, B. O., Kotite, L., Todd, K. M., & Havel, R. J. (1993). Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. *Proceedings of the National Academy of Sciences*, 90(5), 2069-2073.
32. Wouters, K., Shiri-Sverdlov, R., van Gorp, P. J., van Bilsen, M., & Hofker, M. H. (2005). Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. *Clinical Chemistry and Laboratory Medicine (CCLM)*, 43(5), 470-479.
33. Amarenco, P., & Labreuche, J. (2009). Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. *The Lancet Neurology*, 8(5), 453-463.
34. Gao, W., He, H. W., Wang, Z. M., Zhao, H., Lian, X. Q., Wang, Y. S., ... & Wang, L. S. (2012). Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. *Lipids in health and disease*, 11(1), 1-8.
35. Barbara, G. W., Joseph, T. D., Terry, L. S., & Cindy, H. (2005). *Pharmacotherapy Handbook*. Mcgraw-Hill publications, 6, 92-96.
36. Gupta, A., Sehgal, V., & Mehan, S. (2011). Hyperlipidemia: an updated review. *Inter. J. Biopharm. Toxicol. Res*, 1, 81-89.
37. Robbins and Cotran. (2004). *Pathological Basics of disease*. Published by Elsevier, 6, 158.
38. Gupta, A., Sehgal, V., & Mehan, S. (2011). Hyperlipidemia: an updated review. *Inter. J. Biopharm. Toxicol. Res*, 1, 81-89.
39. Pamela, C. C., Richard, A. H., & Denise, R. F. (2005). Cholesterol and Steroid Metabolism. In: Lippincott's Illustrated Review- Biochemistry. Lippincott Williams & Wilkins, Philadelphia, 3, 217-242.
40. Murugesu, M., & Gunapadam, M. V. (2006). Dept of Indian Medicine and Homeopathy, Chennai. Govt of Tamilnadu, 1, 470-80.
41. Khanna, A. K., Chander, R., Singh, C., Srivastava, A. K., & Kapoor, N. K. (1992). Hypolipidemic activity of *Achyranthus aspera* Linn in normal and triton induced hyperlipemic rats. *Indian journal of experimental biology*, 30(2), 128-130.
42. Lakshmi, B. V. S., Neelima, N., Kasthuri, N., Umarani, V., & Sudhakar, M. (2011). Antihyperlipidemic activity of *Bauhinia purpurea* extracts in hypercholesterolemic albino rats. *Int J Pharm Tech Res*, 3(3), 1265-1272.
43. Varsha, D., Shubhangi, S., Mangesh, P., & Naikwade, N. S. (2010). Antihyperlipidemic activity of *Cinnamomum tamala* Nees. on high cholesterol diet induced hyperlipidemia. *International Journal of PharmTech Research*, 2(4), 2517-2521.
44. Oben, J., Kuate, D., Agbor, G., Momo, C., & Talla, X. (2006). The use of a *Cissus quadrangularis* formulation in the management of weight loss and metabolic syndrome. *Lipids in Health and Disease*, 5(1), 1-7.
45. Nityanand, S., & Kapoor, N. K. (1971). Hypocholesterolemic effect of *Commiphora mukul* resin (guggal). *Indian journal of experimental biology*, 9(3), 376-377.
46. Ateş, A., Esen Gürsel, F., Bilal, T., & Altuner, A. (2012). Effect of dietary *Garcinia cambogia* extract on serum lipid profile and serum enzymes in rats fed high-lipid diet. *Iranian Journal of Veterinary Research*, 13(1), 1-7.
47. Bishayee, A., & Chatterjee, M. (1994). Hypolipidaemic and antiatherosclerotic effects of oral *Gymnema sylvestre* R. Br. Leaf extract in albino rats fed on a high fat diet. *Phytotherapy Research*, 8(2), 118-120.
48. Jeyabalan, S., & Palayan, M. (2009). Antihyperlipidemic activity of *Sapindus emarginatus* in Triton WR-1339 induced albino rats. *Research Journal of Pharmacy and Technology*, 2(2), 319-323.
49. Srinivasan, M. R., & Satyanarayana, M. N. (1981). Effect of black pepper (*Piper nigrum* Linn) and piperine on growth, blood constituents and organ weight in rats. *Nutrition Reports International*, 23(5), 871-876.
50. Lau, C. W., Yao, X. Q., Chen, Z. Y., Ko, W. H., & Huang, Y. (2001). Cardiovascular actions of berberine. *Cardiovascular drug reviews*, 19(3), 234-244.
51. Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., ... & Jiang, J. D. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. *Nature medicine*, 10(12), 1344-1351.
52. Varady, K. A., Wang, Y., & Jones, P. J. (2003). Role of policosanols in the prevention and treatment of cardiovascular disease. *Nutrition reviews*, 61(11), 376-383.
53. Gouni-Berthold, I., & Berthold, H. K. (2002). Policosanols: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. *American heart journal*, 143(2), 356-365.
54. Davalos, A., Fernandez-Hernando, C., Cerrato, F., Martínez-Botas, J., Gomez-Coronado, D., Gomez-Cordoves, C., & Lasuncion, M. A. (2006). Red grape juice polyphenols alter cholesterol homeostasis and increase LDL-receptor activity in human cells in vitro. *The Journal of nutrition*, 136(7), 1766-1773.

55. Kumar, M., Nagpal, R., Kumar, R., Hemalatha, R., Verma, V., Kumar, A., ... & Yadav, H. (2012). Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. *Experimental diabetes research*, 2012, 902-917.
56. Taranto, M. P., Medici, M., Perdigon, G., Holgado, A. R., & Valdez, G. F. (1998). Evidence for hypocholesterolemic effect of *Lactobacillus reuteri* in hypercholesterolemic mice. *Journal of dairy science*, 81(9), 2336-2340.
57. Abd El-Gawad, I. A., El-Sayed, E. M., Hafez, S. A., El-Zeini, H. M., & Saleh, F. A. (2005). The hypocholesterolaemic effect of milk yoghurt and soy-yoghurt containing bifidobacteria in rats fed on a cholesterol-enriched diet. *International Dairy Journal*, 15(1), 37-44.
58. Liong, M. T., & Shah, N. P. (2005). Bile salt deconjugation ability, bile salt hydrolase activity and cholesterol co-precipitation ability of lactobacilli strains. *International Dairy Journal*, 15(4), 391-398.
59. Patch, C. S., Tapsell, L. C., Williams, P. G., & Gordon, M. (2006). Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence. *Vascular health and risk management*, 2(2), 157-162.
60. Jones, P. J., Raeini-Sarjaz, M., Ntanios, F. Y., Vanstone, C. A., Feng, J. Y., & Parsons, W. E. (2000). Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. *Journal of lipid research*, 41(5), 697-705.
61. Von Bergmann, K., Sudhop, T., & Lütjohann, D. (2005). Cholesterol and plant sterol absorption: recent insights. *The American journal of cardiology*, 96(1), 10-14.
62. Endo A, M. K. (1979). A new hypocholesterolemic agent produced by a *Monascus* species. *J Antibiot*, 32(8), 852-854.
63. Chen, C. H., Yang, J. C., Uang, Y. S., & Lin, C. J. (2013). Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. *International journal of pharmaceuticals*, 444(1-2), 18-24.
64. Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., ... & Jiang, J. D. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. *Nature medicine*, 10(12), 1344-1351.
65. Cameron, J., Ranheim, T., Kulseth, M. A., Leren, T. P., & Berge, K. E. (2008). Berberine decreases PCSK9 expression in HepG2 cells. *Atherosclerosis*, 201(2), 266-273.
66. Kong, W. J., Wei, J., Zuo, Z. Y., Wang, Y. M., Song, D. Q., You, X. F., ... & Jiang, J. D. (2008). Combination of simvastatin with berberine improves the lipid-lowering efficacy. *Metabolism*, 57(8), 1029-1037.

**CITATION:** Radheshyam & Navneet Kumar Verma (2021). An Updated Review on Hyperlipidemia. *South Asian Res J Pharm Sci*, 3(6): 78-89.